Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAYHIT1: ianalumab versus placebo with first-line corticosteroids in primary immune thrombocytopenia
CTR20231085Phase 3Active
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing ianalumab + first-line corticosteroids with placebo + first-line corticosteroids (2 arms). Primary endpoint: Stable remission off treatment at 12 months. Started Sep 2023; status: active.
02
Drugs
ianalumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20231085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231085.